All Practice Exams

Free Practice Questions for Lebanon Pharmacy Colloquium

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Lebanese Healthcare Colloquium Licensing Examinations (MEHE / MOPH)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Exam Review

Key Facts: Lebanon Pharmacy Colloquium Exam

Written + Oral + Practical

Examination Components

Decree No. 9276, Art. 5

12/20

Pass Mark (Written and Overall)

Decree No. 9276, Art. 5

2 Sessions

Annual Exam Sittings

DGHE Colloquium circulars

OPL License

Professional Licensing

Order of Pharmacists of Lebanon

EN & FR

Delivery Languages

MEHE DGHE Policies

Lebanese University

Body Conducting the Examination

Decree No. 9276, Art. 4

The Lebanese Pharmacy Colloquium is the national licensing examination required for a practice licence from the Ministry of Public Health and registration with the Order of Pharmacists of Lebanon (OPL). Organised by MEHE/DGHE with MOPH and conducted by the Lebanese University, it comprises written, oral and practical components under Decree No. 9276, which sets a 12/20 pass threshold and a practical-component floor of 8/20. Tested areas span pharmacology, pharmacotherapy, clinical pharmacy, pharmaceutics and pharmacy law. This bank offers 100 English-language study questions covering the written component's knowledge base.

Sample Lebanon Pharmacy Colloquium Practice Questions

Try these sample questions to review concepts for the Lebanon Pharmacy Colloquium exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 64-year-old male with symptomatic heart failure with reduced ejection fraction (HFrEF, LVEF 28%, NYHA Class III) is being discharged from the hospital. He is currently taking furosemide 40 mg PO daily and carvedilol 12.5 mg PO BID. Laboratory results show serum potassium 4.2 mEq/L, eGFR 58 mL/min/1.73m², and blood pressure 118/74 mmHg. According to international and Lebanese clinical guidelines for guideline-directed medical therapy (GDMT), which of the following represents the most appropriate regimen to optimize the four foundational pillars of HFrEF mortality reduction?
A.Initiate sacubitril/valsartan, spironolactone, and dapagliflozin while maintaining carvedilol
B.Switch carvedilol to atenolol, initiate lisinopril, and add amlodipine
C.Add digoxin, isosorbide dinitrate/hydralazine, and continue carvedilol monotherapy
D.Initiate enalapril and ivabradine while discontinuing carvedilol due to low blood pressure
Explanation: Modern clinical guidelines for HFrEF (ACC/AHA/HFSA and ESC) mandate quadruple foundational therapy ('the 4 pillars') to reduce mortality and heart failure hospitalizations: (1) an ARNI (sacubitril/valsartan) preferred over ACEi/ARB, (2) an evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) a mineralocorticoid receptor antagonist (MRA such as spironolactone or eplerenone), and (4) an SGLT2 inhibitor (dapagliflozin or empagliflozin). With K+ 4.2 mEq/L and eGFR 58 mL/min/1.73m², initiating sacubitril/valsartan, spironolactone, and dapagliflozin alongside his current carvedilol is fully indicated.
2A 52-year-old female with type 2 diabetes mellitus is newly diagnosed with stage 1 hypertension (BP 138/88 mmHg confirmed on repeated visits). Urinalysis reveals persistent microalbuminuria with a urinary albumin-to-creatinine ratio (UACR) of 180 mg/g. Which of the following antihypertensive drug classes is considered the first-line therapy of choice due to its proven nephroprotective benefits?
A.Beta-adrenergic blocker (e.g., bisoprolol)
B.Dihydropyridine calcium channel blocker (e.g., amlodipine)
C.Thiazide-like diuretic (e.g., indapamide)
D.Angiotensin-converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB)
Explanation: In diabetic patients with persistent microalbuminuria (UACR ≥ 30 mg/g) or overt proteinuria, an ACE inhibitor (e.g., ramipril, enalapril) or an ARB (e.g., losartan, valsartan) is the mandatory first-line agent. These agents selectively dilate the efferent renal arteriole, lowering intraglomerular hydrostatic pressure, reducing albumin excretion, and slowing the progression of diabetic nephropathy.
3A 58-year-old male with chronic non-valvular atrial fibrillation undergoes mechanical mitral valve replacement. His cardiologist asks the clinical pharmacist regarding oral anticoagulation therapy. Which of the following regimens is strictly indicated in this patient?
A.Warfarin adjusted to a target INR of 2.5–3.5
B.Apixaban 5 mg PO BID
C.Rivaroxaban 20 mg PO once daily with the evening meal
D.Dabigatran etexilate 150 mg PO BID
Explanation: Warfarin (a vitamin K antagonist) remains the only approved and safe oral anticoagulant for patients with mechanical prosthetic heart valves. Direct oral anticoagulants (DOACs like dabigatran, apixaban, rivaroxaban, and edoxaban) are strictly contraindicated in mechanical heart valves because clinical trials (such as RE-ALIGN with dabigatran) demonstrated significantly increased rates of thromboembolism and major bleeding. For a mechanical mitral valve, the recommended target INR is 2.5–3.5 (or 3.0).
4A 60-year-old male is admitted with an acute non-ST-elevation myocardial infarction (NSTEMI) and undergoes successful percutaneous coronary intervention (PCI) with a drug-eluting stent. His baseline fasting lipid panel shows LDL-C of 145 mg/dL. According to dyslipidemia clinical practice guidelines for clinical atherosclerotic cardiovascular disease (ASCVD), which lipid-lowering regimen should be initiated prior to hospital discharge?
A.Pravastatin 40 mg PO once daily
B.Simvastatin 20 mg PO once daily
C.Atorvastatin 80 mg PO once daily
D.Fenofibrate 145 mg PO once daily
Explanation: All patients with established clinical ASCVD (secondary prevention) require high-intensity statin therapy, which lowers LDL-C by ≥ 50%. The two approved high-intensity statin regimens are Atorvastatin 40–80 mg daily and Rosuvastatin 20–40 mg daily. Atorvastatin 80 mg is standard therapy post-ACS to stabilize plaque and reduce recurrent cardiovascular events.
5A 55-year-old woman presents to the community pharmacy with a headache. Her blood pressure is measured at 195/115 mmHg. She has no chest pain, shortness of breath, neurological deficits, visual changes, or nausea. What key clinical feature distinguishes a hypertensive emergency from hypertensive urgency, and what is the appropriate pharmaceutical care approach for this patient?
A.The presence of acute, progressive target organ damage distinguishes emergency from urgency; this patient has hypertensive urgency and should be managed with oral antihypertensive agents and close outpatient follow-up
B.The absolute systolic blood pressure value above 180 mmHg defines an emergency; she requires immediate IV nitroprusside in an intensive care setting
C.The diastolic blood pressure above 110 mmHg indicates an emergency; she should immediately take sublingual nifedipine capsules in the community pharmacy
D.Hypertensive emergency is defined solely by symptoms of headache; she must be given IV furosemide immediately
Explanation: A hypertensive crisis (BP > 180/120 mmHg) is classified as a hypertensive emergency ONLY if there is evidence of acute, progressing target organ damage (e.g., encephalopathy, acute coronary syndrome, aortic dissection, acute pulmonary edema, or acute renal failure). In the absence of acute end-organ damage, the condition is classified as hypertensive urgency. Hypertensive urgency should be managed cautiously using oral antihypertensive medications with a gradual blood pressure reduction over 24–48 hours; rapid reduction is dangerous as it can precipitate cerebral or myocardial hypoperfusion.
6A 34-year-old previously healthy male with no significant medical history and no recent antibiotic exposure presents to an ambulatory clinic with fever, productive cough, and right lower lobe consolidation confirmed by chest X-ray. He is diagnosed with community-acquired pneumonia (CAP) suitable for outpatient treatment. According to clinical guidelines (ATS/IDSA), which of the following is the first-line oral empirical monotherapy of choice?
A.Vancomycin 250 mg PO QID
B.Ciprofloxacin 500 mg PO BID
C.Cefuroxime axetil 250 mg PO BID
D.Amoxicillin 1 g PO TID
Explanation: For healthy outpatients with CAP without comorbidities or risk factors for antibiotic-resistant pathogens, first-line recommendations are Amoxicillin 1 g PO TID (preferred for Streptococcus pneumoniae coverage), Doxycycline 100 mg PO BID, or a macrolide (azithromycin) only in areas with pneumococcal macrolide resistance < 25%. High-dose amoxicillin provides excellent coverage against the primary pathogen, Streptococcus pneumoniae.
7A 24-year-old non-pregnant female presents to the pharmacy complaining of burning on urination (dysuria), urinary frequency, and urgency for the past 24 hours. She has no fever, flank pain, vaginal discharge, or prior history of urinary tract infections. Which of the following oral regimens represents a first-line treatment for acute uncomplicated cystitis?
A.Nitrofurantoin monohydrate/macrocrystals 100 mg PO BID for 5 days
B.Ciprofloxacin 500 mg PO BID for 7 days
C.Amoxicillin 500 mg PO TID for 10 days
D.Azithromycin 500 mg PO single dose
Explanation: First-line empirical treatments for acute uncomplicated cystitis per IDSA guidelines are: Nitrofurantoin monohydrate/macrocrystals 100 mg BID for 5 days, Fosfomycin trometamol 3 g single oral dose, or Trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg (1 DS tablet) BID for 3 days (if local E. coli resistance is < 20%). Nitrofurantoin concentrates in the bladder urine with minimal systemic absorption, making it safe, effective, and sparing of collateral flora.
8A 68-year-old hospitalized patient develops hospital-acquired pneumonia (HAP) 5 days after admission. Sputum Gram stain reveals Gram-negative bacilli, and empirical therapy against Pseudomonas aeruginosa is required. Which of the following beta-lactam antibiotics lacks antipseudomonal activity and would be INAPPROPRIATE for this patient?
A.Meropenem
B.Piperacillin/tazobactam
C.Cefepime
D.Ertapenem
Explanation: Ertapenem is unique among carbapenems because it lacks activity against the 'PEA' group: Pseudomonas aeruginosa, Enterococcus species, and Acinetobacter baumannii. In contrast, piperacillin/tazobactam, cefepime, ceftazidime, meropenem, and imipenem/cilastatin all have reliable activity against Pseudomonas aeruginosa.
9A clinical pharmacist reviews the mechanism of action of vancomycin used in the management of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. By which specific molecular mechanism does vancomycin inhibit bacterial cell wall synthesis?
A.Binding to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors, blocking transglycosylation and transpeptidation
B.Inhibiting bacterial DNA-dependent RNA polymerase, halting mRNA transcription
C.Binding covalently to penicillin-binding protein 2a (PBP2a), preventing peptidoglycan cross-linking
D.Binding to the 50S ribosomal subunit, preventing peptide chain elongation
Explanation: Vancomycin is a tricyclic glycopeptide antibiotic that binds with high affinity to the D-Ala-D-Ala terminus of cell wall peptidoglycan precursors (lipid II). This sterically hinders both transglycosylation (elongation of the peptidoglycan polymer chain) and transpeptidation (cross-linking), leading to osmotic cell lysis.
10A blood culture from a septic patient grows Klebsiella pneumoniae producing an Extended-Spectrum Beta-Lactamase (ESBL). According to microbiological and clinical trial evidence (e.g., the MERINO trial), which antibiotic class represents the definitive first-line treatment of choice for severe bloodstream infections caused by ESBL-producing Enterobacterales?
A.Carbapenems (e.g., Meropenem)
B.Ureidopenicillin/beta-lactamase inhibitor combinations (e.g., Piperacillin/tazobactam)
C.Third-generation cephalosporins (e.g., Ceftriaxone)
D.Fluoroquinolones (e.g., Ciprofloxacin monotherapy)
Explanation: Carbapenems (meropenem, imipenem, or ertapenem) are the definitive drug of choice for serious infections caused by ESBL-producing Enterobacterales. The landmark MERINO trial demonstrated that piperacillin/tazobactam resulted in significantly higher 30-day mortality compared to meropenem for ESBL bacteremia, establishing carbapenems as the standard of care.

About the Lebanon Pharmacy Colloquium Exam

The Lebanon Pharmacy Colloquium (Colloque de Pharmacie / امتحان الكولوكيوم في الصيدلة) is the national licensing examination that pharmacy graduates must pass to practise in Lebanon. Law No. 367/1994 (Art. 3) makes success in the Colloquium — conducted by the ministry responsible for higher education — a statutory condition of the pharmacy practice licence, and Decree No. 9276 of 5 October 1996 applies the examination to graduates of faculties operating in Lebanon and abroad without exception. Art. 5 of that decree sets three components for pharmacy: a written examination, an oral examination and a practical examination. Tested areas include pharmacology and disease-state pharmacotherapy, clinical pharmacy interventions, adverse drug reaction monitoring, dosage form design and stability, biopharmaceutics and pharmacokinetics, medicinal chemistry, natural products, and Lebanese pharmacy law and ethics. The 2026 Directorate General of Higher Education notice confirmed that Colloquium examinations are held in French or English only. This bank is an independent English-language MCQ study adaptation by OpenExamPrep; it supports the knowledge tested on the written paper and is not a substitute for the oral and practical components.

Exam sponsor: Directorate General of Higher Education (MEHE) & Ministry of Public Health (MOPH) in coordination with the Order of Pharmacists of Lebanon (OPL). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Lebanese Pharmacy Colloquium (Colloque de Pharmacie) is organised by the Ministry of Education and Higher Education with the Ministry of Public Health, and conducted by the Lebanese University Faculty of Pharmacy under Decree No. 9276 (Art. 4). It runs in two sessions per year (first and second session) whose dates are fixed by DGHE circular; for 2026, first-session applications ran from 2 March to 15 June 2026. Art. 5 of the decree sets three components for pharmacy: a written examination, an oral examination and a practical examination. Tested areas span pharmacology, pharmacotherapy, clinical pharmacy, pharmaceutics, medicinal chemistry, pharmacognosy, and pharmacy law and ethics. Passing the Colloquium is a statutory condition of licensure under Law No. 367/1994 (Art. 3), alongside registration with the Order of Pharmacists of Lebanon. This bank provides 100 English-language study questions and covers only the knowledge layer of the written component.

Time Limit

Not published in the DGHE notices; the oral and practical examinations are scheduled on separate session dates

Passing Score

Decree No. 9276 (Art. 5): at least 12/20 on the written paper to sit the oral and practical examinations, at least 12/20 overall across the three components, and not less than 8/20 on the practical examination

Exam / Certification Fees

A lump-sum registration fee collected by MEHE and fixed by decree taken in the Council of Ministers (Law No. 367/1994, Art. 94); the amount is not published in the statute. MEHE launched electronic payment of Colloquium fees in July 2026

Exam sponsor website

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

30%

Pharmacology & Pharmacotherapy

Mechanism of action, therapeutic regimens, adverse effects, and contraindications across major drug classes and disease states.

25%

Clinical Pharmacy, Patient Care & Toxicology

Therapeutic drug monitoring, drug interactions, renal/hepatic dose adjustments, toxic syndromes and antidotes, and patient counseling.

15%

Pharmaceutics & Biopharmaceutics

Formulation science, drug absorption and bioavailability, clearance kinetics, half-life calculations, and physical chemical stability.

15%

Medicinal Chemistry & Pharmacognosy

Chemical structures, functional group properties, metabolic transformation pathways, bioactive phytoconstituents, and herbal safety.

15%

Pharmacy Law, Ethics & Public Health

Lebanese pharmaceutical regulations, controlled substances schedules, prescription handling, OPL professional ethics, and public health.

Preparing for the Lebanon Pharmacy Colloquium Exam

What You Need to Know

  • Passing score: Decree No. 9276 (Art. 5): at least 12/20 on the written paper to sit the oral and practical examinations, at least 12/20 overall across the three components, and not less than 8/20 on the practical examination
  • Assessment: The Lebanese Pharmacy Colloquium (Colloque de Pharmacie) is organised by the Ministry of Education and Higher Education with the Ministry of Public Health, and conducted by the Lebanese University Faculty of Pharmacy under Decree No. 9276 (Art. 4). It runs in two sessions per year (first and second session) whose dates are fixed by DGHE circular; for 2026, first-session applications ran from 2 March to 15 June 2026. Art. 5 of the decree sets three components for pharmacy: a written examination, an oral examination and a practical examination. Tested areas span pharmacology, pharmacotherapy, clinical pharmacy, pharmaceutics, medicinal chemistry, pharmacognosy, and pharmacy law and ethics. Passing the Colloquium is a statutory condition of licensure under Law No. 367/1994 (Art. 3), alongside registration with the Order of Pharmacists of Lebanon. This bank provides 100 English-language study questions and covers only the knowledge layer of the written component.
  • Time limit: Not published in the DGHE notices; the oral and practical examinations are scheduled on separate session dates
  • Exam / certification fees: A lump-sum registration fee collected by MEHE and fixed by decree taken in the Council of Ministers (Law No. 367/1994, Art. 94); the amount is not published in the statute. MEHE launched electronic payment of Colloquium fees in July 2026 Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Lebanon Pharmacy Colloquium: Suggested Study Strategy

1Master high-risk drug monitoring parameters (e.g., aminoglycosides, vancomycin, digoxin, lithium, phenytoin, and warfarin).
2Review the Cockcroft-Gault equation and practice calculating creatinine clearance for drug dosage adjustments.
3Review major antimicrobial classes, mechanisms of action, typical pathogens covered, and primary resistance patterns.
4Familiarize yourself with common toxic syndromes (anticholinergic, cholinergic, opioid, sympathomimetic) and their specific antidotes.

Frequently Asked Questions

What does the Lebanese Pharmacy Colloquium examination consist of?

Decree No. 9276 (Art. 5) sets three components for pharmacy: a written examination, an oral examination and a practical examination. Only candidates scoring at least 12/20 on the written paper may sit the oral and practical examinations, and the practical mark must not fall below 8/20 for a final pass.

Who is required to sit for the Pharmacy Colloquium?

Decree No. 9276 (Art. 5) subjects holders of a pharmacy degree from faculties and institutes operating in Lebanon and abroad, without exception, to the Colloquium, and Law No. 367/1994 (Art. 3) makes passing it a condition of the practice licence alongside registration with the Order of Pharmacists of Lebanon. Degrees obtained by correspondence study are not admitted to the examination.

In what languages is the exam administered?

Candidates may take the official exam in English or French according to the primary language of instruction at their degree-granting institution. This question bank is an English-language study adaptation developed by OpenExamPrep.

When are the Pharmacy Colloquium sessions held?

The Directorate General of Higher Education runs two sessions per year, announced as the first session (الدورة الأولى) and the second session (الدورة الثانية). Dates are set by circular rather than by fixed calendar months: for 2026, first-session applications were accepted from 2 March to 15 June 2026, with university-equivalency files due by 30 April 2026.

How are registration fees paid for the exam?

Law No. 367/1994 (Art. 94) requires MEHE to collect a lump-sum registration fee from every Colloquium candidate, with the amount fixed by decree taken in the Council of Ministers. Candidates must pay within one week of their application being accepted, and MEHE announced the move of Colloquium services to electronic fee payment in July 2026.